<DOC>
	<DOCNO>NCT00308451</DOCNO>
	<brief_summary>The purpose propose work ass effect dietary supplement , contain chromium ( 600 mcg per day ) provide chromium picolinate biotin ( 2 mg per day ) glycemic control type 2 diabetes . Specifically , study ass whether use supplement lower post-prandial rise blood glucose experience ingestion 75g carbohydrate load , relative placebo , type 2 diabetic patient . The study also assess chronic effect supplementation 4-week period ( relative placebo ) fast plasma level glucose , insulin , lipids lipoprotein .</brief_summary>
	<brief_title>A 30 Day Acute Efficacy Safety Study Chromium Picolinate + Biotin Glycemic Control Overweight Obese Subjects With T2DM</brief_title>
	<detailed_description>The purpose work ass effect dietary supplement , contain chromium ( 600 mcg per day ) provide chromium picolinate biotin ( 2 mg per day ) glycemic control type 2 diabetes currently take oral antidiabetic agent ( OAD ) fail therapy OADs . Subjects enter trial must HbA1c &gt; /= 7.0 % OGTT &gt; /= 200 mg/dL 2 hour post consumption 75 g glucose beverage . The study acute 30 day intervention conjunction subject 's current OADs standard care comparison placebo . Specifically , study ass whether use supplement lower post-prandial rise blood glucose experience ingestion 75g carbohydrate load , relative placebo , type 2 diabetic patient measure area curve glucose ( AUCg ) . The study also assess acute effect supplementation 4-week period ( relative placebo ) fast plasma level glucose , fructosamine , insulin , lipids lipoprotein .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Picolinic acid</mesh_term>
	<mesh_term>Chromium</mesh_term>
	<mesh_term>Biotin</mesh_term>
	<criteria>1 . Diagnosis type 2 diabetes &gt; 12 month . 2 . Postprandial blood glucose ( glucose &gt; 200 mg/dl ) level consistent ADA diagnosis diabetes confirm screen visit . 3 . Male female age 18 65 year . 4 . HbA1c &gt; 7.0 % . 5 . Use treatment regimen include diet exercise and/or drug therapy diabetes allow . Drug therapy may include alphaglucosidase inhibitor ( e.g . acarbose , voglibose , miglitol ) oral hypoglycemic agent sulfonylureas metformin thiazolidinediones ( TZDs ) . Insulin use allowable 6 . No change medication dosage within 60 day prior enter trial . 7 . Subjects body mass index ( BMI ) &gt; 25 &lt; 35 . 8 . Fasting triglyceride &lt; 400 . [ 32 ] 9 . Willing complete study related requirement . 10 . Subject provide write consent participate trial consent must give voluntarily . 1 . Diagnosis type I diabetes . 2 . Hypoglycemic event require EMS intervention &lt; 12 month . 3 . Diabetic Ketoacidosis ( DKA ) &lt; 12 month . 4 . Subjects take supplement contain chromium within previous 90 day prior toenrollment . 5 . Creatinine &gt; 2.0 x ULN ; AST ALT &gt; 2.0 x ULN ; Total Bilirubin &gt; 1.5 x ULN . 6 . COPD , CHF , Angina , HTN , MI , CVD require hospitalization within previous 12 month . 7 . History cerebrovascular accident ( CVA ) , pulmonary embolism ( PE ) , unresolved deep vein thrombosis ( DVT ) . 8 . History CABG , PTCA , reperfusion therapy &lt; 12 month . 9 . Uncontrolled high blood pressure ( seat : systolic &gt; 160 mmHg diastolic &gt; 90 mmHg ) 10 . History serious immunosuppressive disorder undergo current immunosuppressive therapy . 11 . Female subject pregnant nursing , plan become pregnant study . No hormone replacement therapy postmenopausal subject . 12 . Hepatic disease , impaired thyroid , impaired renal function , diseases know affect glucose lipid metabolism . TSH must within range normality enter trial . 13 . Diagnosed selfreported alcoholism substanceabuse problem 14 . Any psychiatric mental health issue would prevent subject complete study 15 . Any illness complication factor , opinion investigator , would jeopardize subject â€™ health well participate study would interfere subject successfully complete study . 16 . Current participation clinical research trial product device , participation say clinical trial within 30 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>chromium</keyword>
	<keyword>chromium picolinate</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>fructosamine</keyword>
	<keyword>glycemic control</keyword>
	<keyword>OGTT</keyword>
</DOC>